The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).
 
Nabil F. Saba
Honoraria - Bristol-Myers Squibb; Lilly; Merck; Pfizer
 
Seth D Force
No Relationships to Disclose
 
Charles A. Staley
No Relationships to Disclose
 
Felix G Fernandez
No Relationships to Disclose
 
Field F. Willingham
Research Funding - Cancer Prevention Pharmaceuticals (Inst); Cook Medical (Inst); RedPath (Inst); Xlumena (Inst)
 
Pickens Allan
No Relationships to Disclose
 
Kenneth Cardona
No Relationships to Disclose
 
Zhengjia Chen
No Relationships to Disclose
 
Dana Backlund Cardin
Consulting or Advisory Role - Merrimack
Research Funding - Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Oncolytics (Inst); Roche (Inst); Synta (Inst)
 
Eric Lambright
No Relationships to Disclose
 
Jon Nesbitt
No Relationships to Disclose
 
Kristin Ann Higgins
No Relationships to Disclose
 
R Donald Harvey
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Eisai; G1 Therapeutics; Genentech/Roche; Lilly; Novartis; Sandoz; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
 
Suresh S. Ramalingam
No Relationships to Disclose
 
Dong Moon Shin
No Relationships to Disclose
 
Jonathan Jay Beitler
Stock and Other Ownership Interests - GE Healthcare
 
Bassel F. El-Rayes
No Relationships to Disclose
 
Jerome C Landry
No Relationships to Disclose
 
Anuradha Bapsi Chakravarthy
Research Funding - Bayer/Onyx (Inst); Novartis (Inst); Xoft (Inst)